Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.57 |
| ▸ | AURKA | O14965 | 5/20 | 0.57 |
| ▸ | MET | P08581 | 5/20 | 0.57 |
| ▸ | TEK | Q02763 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.48 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132794 | 0.87 | LMNA (0.50) | KDRAURKBAURKAMETTEK | |
| SCHEMBL21776575 | 0.86 | AXL (0.50) | KDRAURKBAURKAMETTEK | |
| SCHEMBL22923825 | 0.86 | KDR (0.57) | KDRAURKBAURKAMETTEK | |
| SCHEMBL13220555 | 0.86 | KDR (0.57) | KDRAURKBAURKAMETTEK | |
| SCHEMBL31218187 | 0.84 | KDR (0.56) | KDRAURKBAURKAMETTEK | |
| SCHEMBL1323767 | 0.84 | KDR (0.56) | KDRAURKBAURKAMETTEK | |
| SCHEMBL23753739 | 0.83 | AXL (0.52) | KDRAURKBAURKAMETTEK | |
| SCHEMBL28429529 | 0.82 | KDR (0.59) | KDRAURKBAURKAMETTEK | |
| SCHEMBL165285 | 0.81 | PDGFRB (0.55) | ABL1LCKRIPK2PDGFRBPDGFRA | |
| SCHEMBL29492471 | 0.81 | PDGFRB (0.55) | ABL1LCKRIPK2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874420-B | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-116874420-A | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-107305202-B | HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard | 北京睿创康泰医药研究院有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-107305202-A | The HPLC methods and impurity that analysis methanesulfonic acid pleasure is cut down for Buddhist nun and its preparation impurity make the purposes of reference standard | 北京睿创康泰医药研究院有限公司 | 2017-10-31 | — | — | CN | claimed |
| CN-116751162-B | Quinoline compound, preparation method thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2025-02-28 | — | — | CN | disclosed |
| CN-116874420-B | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116874420-B | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116874420-A | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116874420-A | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116751162-A | Quinoline compound, preparation method thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2023-09-15 | — | — | CN | disclosed |
| CN-111892536-B | Substituted quinoline carboxamides and their use | 北京福元医药股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2022-02-01 | — | — | US | disclosed |
| US-9504746-B2 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-8969379-B2 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969379-B2 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20130237565-A1 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20130237565-A1 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20080214604-A1 | 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and a compound such as one of magnesium oxide, calcium oxide, sodium carbonate, disodium hydrogenphosphate, sodium citrate, sodium hydrogencarbonate, and sodium hydroxide and/or silicic acid or salt; stabilization | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214604-A1 | 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and a compound such as one of magnesium oxide, calcium oxide, sodium carbonate, disodium hydrogenphosphate, sodium citrate, sodium hydrogencarbonate, and sodium hydroxide and/or silicic acid or salt; stabilization | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1797881-A1 | MEDICINAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237565-A1 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CMA1, CA7 | KDR 4435/4885AURKB 2432/4885AURKA 418/4885 |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | UGT1A1, CYP4B1, CYP1B1 | KDR 4267/4885AURKB 3656/4885AURKA 2188/4885 |
| US-20080214604-A1 | 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and a compound such as one of magnesium oxide, calcium oxide, sodium carbonate, disodium hydrogenphosphate, sodium citrate, sodium hydrogencarbonate, and sodium hydroxide and/or silicic acid or salt; stabilization | CA2, CA7, CA4 | KDR 4563/4885AURKB 1880/4885AURKA 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.